Shetty said Neobiocon would introduce world-class pharma biotech products to the Emirates. "Biotherapeutics for cardiovascular diabetes and oncology segments represent the fastest growing class of drugs in the $5 billion GCC (Gulf Cooperation Council) pharmaceutical market," he pointed out.
"We will offer products that cater to lifestyle disorders and oncology. We will also produce immuno-suppressant drugs," affirmed Shetty, a non-resident Indian.
Advertisement
Studies have shown high mortality rates due to diabetes and cardiovascular disorders in the Gulf region. Disease incidence is alarmingly high. Besides India and sub-Saharan Africa, countries in the Gulf and West Asia are prone to such life-threatening diseases due to changing lifestyle and occupational hazards.
"Obesity is also a common, serious and growing problem. Current epidemiological estimates suggest around 1.1 billion people worldwide are above their standard weight. Developing obesity treatments that target novel pathways is a focus for biopharma firms," Shaw noted.
Besides the UAE, the Dubai office will represent the company in Saudi Arabia, Kuwait, Bahrain, Qatar and Oman.
During the last three years, Neopharma introduced about 70 formulations, including antibiotics, painkillers, anti-allergics and drugs in cardiology and diabetology segments.
Ranked among the top 15 UAE firms, Neopharma is a recipient of the prestigious Mohammed bin Rashid Al Maktoum award in the manufacturing category. It also has the latest European Union good manufacturing practice certificate from Belgium.
Neopharma plans to foray into European markets and work on nanotechnology-based products. Its facility is recognised as a regional contract manufacturing hub for European and Canadian firms.
Source: IANS
LIN/B
Advertisement
Besides the UAE, the Dubai office will represent the company in Saudi Arabia, Kuwait, Bahrain, Qatar and Oman.
During the last three years, Neopharma introduced about 70 formulations, including antibiotics, painkillers, anti-allergics and drugs in cardiology and diabetology segments.
Ranked among the top 15 UAE firms, Neopharma is a recipient of the prestigious Mohammed bin Rashid Al Maktoum award in the manufacturing category. It also has the latest European Union good manufacturing practice certificate from Belgium.
Neopharma plans to foray into European markets and work on nanotechnology-based products. Its facility is recognised as a regional contract manufacturing hub for European and Canadian firms.
Source: IANS
LIN/B
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Corporate News
The first World Health Organisation (WHO)/ International Labour Organisation (ILO) joint global monitoring report shows that more action is needed to ensure healthier, safer, more resilient, and more social workplaces.
Successful career transitions could be possible when people leverage their existing skills in the new occupation. A new Artificial Intelligence tool helps employees figure out the right job according to their current skill set.
AI and big data rule the pharmaceutical sector by enhancing the drug development process and increasing the marketing and sales of drugs
Insurance companies in the US are working towards adding food to their coverage menu to improve the people's health under their coverage and cut hospital costs.
Pharmaceutical companies need to make strategic decisions that will provide financial benefit while showing strong commitment to global health and their patients during the pandemic.
